Zakharova Natal'ya Borisovna, Doctor of medical sciences, professor, sub-department of clinical laboratory diagnostics, Saratov State Medical University named after V. I. Razumovsky (building 2, 112, Bolshaya Kazachya street, Saratov, Russia), E-mail: firstname.lastname@example.org
Maslyakov Vladimir Vladimirovich, Doctor of medical sciences, professor, Vice Rector for Research and Public Relations, Saratov Medical University “Reaviz” (building 10, Verkhny rynok street, Saratov, Russia), E-mail: email@example.com
Gergenreter Yuliya Sergeevna, Oncologist, Regional Clinical Oncology Center (building 1V, Smirnovskoye ushchelye village, Saratov, Russia), E-mail: firstname.lastname@example.org
Fedorov Vladimir Eduardovich, Doctor of medical sciences, professor, sub-department of surgery and oncology, Saratov State Medical University named after V. I. Razumovsky (building 2, 112, Bolshaya Kazachya street, Saratov, Russia), E-mail: email@example.com
Background. Neoplastic transformation of tumor cells in breast cancer is associated with accumulation of genetic disorders during an individual 's lifetime. At present, molecular genetic studies have established the heterogeneous nature of genomic lesions, which determine the nature of the disease, its prognosis and the strategy of treatment of patients. Purpose of the study is to establish changes in VEGF and serum TGFβ1 in breast cancer patients depending on the stage of the disease and the biological subtype of the tumor.
Materials and methods. The study includes 80 patients, aged 50 to 69, with invasive duct and slice cancer of breast, II and III degree of malignancy, various biological subtypes according to immunohistochemical analysis. Patients are divided into groups depending on the stage of the disease and the biological subtypes of breast cancer.
Results. As a result, VEGF and serum TGF-b1 levels in almost all breast cancer patients exceeded those of practically healthy women. However, the most significant change in the level of growth factors occurred in groups of patients with 3-4 stages f disease and in groups with THP, Ner2-positive luminal B, Ner-positive nonluminal breast cancer. The results of the TGF-b1 level study characterize the malignancy of tumor growth and its progression, the rise of VEGF content is an additional indicator of the progression of PMG associated with the adverse prognosis. A rational approach to the use of these markers can increase the relative diagnostic significance of the results obtained.
Conclusions. The build-up of TGF [beta] 1 and VEGF in serum in breast cancer patients is a consequence of the restructuring of the cytokine network of the tumor microenvironment, which determines further tumor progression and metastasis. Determination of growth factors (TGF [beta] 1 and VEGF) in blood serum allows to identify groups of patients at high risk of tumor progression, metastasis, and can be used to predict the course of the disease and choose the algorithm for treating breast cancer patients.
1. Vuong D., Simpson P. T., Green B. et al. Virchows Arch. 2014, vol. 465 (1), pp. 1–14. DOI 10.1007/s00428-014-1593-7.PMID: 24878755.
2. Lyubchenko L. N., Bateneva E. I. Mediko-geneticheskoe konsul'tirovanie i DNKdiagnostika pri nasledstvennoy predraspolozhennosti k raku molochnoy zhelezy i raku yaichnikov [Genetic counseling and DNA diagnostics for a hereditary predisposition to breast and ovarian cancer]. Moscow: Izd. gruppa RONTs, 2014, 64 p. [In Russian]
3. Stenina M. B., Frolova M. A. Prakticheskaya onkologiya [Practical oncology]. 2011, no. 12 (1), pp. 6–11. [In Russian]
4. Nagarsheth N., Wicha M. S., Zou W. Nature Reviews Immunology. 2017, vol. 17 (9), pp. 559–572. DOI 10.1038/nri.2017.49.
5. Wang M., Zhao J., Zhang L. Journal of Cancer. 2017, vol. 8 (5), pp. 761–773. DOI 10.7150/jca.17648
6. Gershteyn E. S., Kushlinskiy D. N., Tereshkina I. V., Ermilova V. D., Ovchinnikova L. K., Galdava D. E., Kuznetsova O. V. Onkoginekologiya [Oncogynecology]. 2015, no. 1, pp. 32–40. [In Russian]
7. Zborovskaya I. B. Uspekhi molekulyarnoy onkologii [Advances in molecular oncology]. 2014, no. 2, pp. 4–15. [In Russian]
8. Semiglazov V. F. Immunologiya raka molochnoy zhelezy [Breast cancer immunology]. Sverdlovsk: Spets. izd-vo med. knig, 2019, 204 p. [In Russian]
9. DeSantis C. E., Bray F., Ferlay J. et al. Cancer Epidemiol. Biomarkers Prev. 2015, vol. 24, pp. 1495–1506.
10. Semiglazov V. F., Semiglazov V. V. Rak molochnoy zhelezy. Biologiya, mestnoe i sistemnoe lechenie [Mammary cancer. Biology, local and systemic treatment]. Moscow: SIMK, 2014, 352 p. [In Russian]
11. Kolyadina I. V., Poddubnaya I. V., Komov D. V., Kerimov R. A., Roshchin E. M., Makarenko N. P. Sibirskiy onkologicheskiy zhurnal [Siberian oncological journal]. 2008, no. 6, pp. 17–20. [In Russian]
12. Chen C., Zhao K. N., Masci P. P., Lakhani S. R., Antonsson A., Simpson P. T. et al. BMC Cancer. 2015, vol. 15, p. 1010. DOI 10.1186/s12885-015-1993-3.
13. deKruijf E. M., Dekker T. J., Hawinkels L. J., Putter H., Smit V. T., Kroep J. R. et al. Ann Oncol. 2013, vol. 24 (2), pp. 384–390. DOI 10.1093/annonc/mds333